The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer

Related articles

1. DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab

   This article has 23 authors:

   1. Bingnan Zhang
   2. Lingzhi Hong
   3. Kaiwen Wang
   4. C. Allison Stewart
   5. Komal Shah
   6. Wei-lien Wang
   7. Alejandra Serrano
   8. Luisa Solis Soto
   9. Robert J. Cardnell
   10. Alexa Halliday
   11. Mitchell Parma
   12. Elyse R. Lopez
   13. Mukulika Bose
   14. Cole Ruoff
   15. Shafqat F. Ehsan
   16. Kavya Ramkumar
   17. Tim Li
   18. Rosy Zheng
   19. Loukia G. Karacosta
   20. Jianjun Zhang
   21. John V. Heymach
   22. Carl M. Gay
   23. Lauren A. Byers

2. Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer

   This article has 2 authors:

   1. Oluwadamilola Arojo
   2. Alan M. Jones

3. Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic review and meta-analysis

   This article has 2 authors:

   1. Seungho Cook
   2. Han Sang Kim